
|Videos|January 24, 2014
Targeted Therapies in Ovarian Cancer
Author(s)Franco M. Muggia, MD
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.
Advertisement
Franco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the challenge of developing targeted therapies to treat ovarian cancer.
Clinical Pearls:
- There have not been many targeted therapies developed in ovarian cancer
- Physicians still rely on a chemotherapy regimen to treat patients with ovarian cancer
- Although this regimen eliminates advanced disease about 80-90% of the time, the disease eventually comes back
- TargetingBRCAand PARP have proven to be good targets to develop further
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































